NewAmsterdam Pharma Company N.V.

Symbol: NAMS




Market price today

  • 87.5675

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 1.95B

    MRK Cap

  • 0.00%

    DIV Yield

NewAmsterdam Pharma Company N.V. (NAMS) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Michael Harvey Davidson FACC, Facp., M.D.
Full-time employees:29
Address:Gooimeer 2-35

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

General Outlook

When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.335%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.206%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.042% return, is a testament to NewAmsterdam Pharma Company N.V.'s adeptness in optimizing resource deployment. NewAmsterdam Pharma Company N.V.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.073%. Furthermore, the proficiency of NewAmsterdam Pharma Company N.V. in capital utilization is underscored by a remarkable -0.077% return on capital employed.

Stock Prices

NewAmsterdam Pharma Company N.V.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $23, while its low point bottomed out at $21.69. This variance in figures offers investors a lucid insight into the roller-coaster ride that is NewAmsterdam Pharma Company N.V.'s stock market.

Liquidity Ratios

Analyzing NAMS liquidity ratios reveals its financial health of the firm. The current ratio of 816.77% gauges short-term asset coverage for liabilities. The quick ratio (805.59%) assesses immediate liquidity, while the cash ratio (805.59%) indicates cash reserves.

Current Ratio816.77%
Quick Ratio805.59%
Cash Ratio805.59%

Profitability Ratios

NAMS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 21.69% underscores its earnings before tax deductions. The effective tax rate stands at 5.08%, revealing its tax efficiency. The net income per EBT, 94.92%, and the EBT per EBIT, -64.79%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -33.47%, we grasp its operational profitability.

Pretax Profit Margin21.69%
Effective Tax Rate5.08%
Net Income per EBT94.92%
EBT per EBIT-64.79%
EBIT per Revenue-33.47%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.17, it details the span from stock purchase to revenue. The 8 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding806
Fixed Asset Turnover711.52
Asset Turnover0.20

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.34, and free cash flow per share, -0.34, depict cash generation on a per-share basis. The cash per share value, 5.90, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.28, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.34
Free Cash Flow per Share-0.34
Cash per Share5.90
Operating Cash Flow Sales Ratio-0.28
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-645.51
Short Term Coverage Ratio-645.51
Capital Expenditure Coverage Ratio-75.02
Dividend Paid and Capex Coverage Ratio-75.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.01%, highlights its total liabilities relative to assets. An interest coverage of 204.36 indicates its ability to manage interest expenses.

Debt Ratio0.01%
Total Debt to Capitalization0.01%
Interest Coverage204.36
Cash Flow to Debt Ratio-645.51
Company Equity Multiplier1.19

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.17, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.15, reflects the portion of profit attributed to each share. The book value per share, 3.51, represents the net asset value distributed per share, while the tangible book value per share, 3.51, excludes intangible assets.

Revenue Per Share0.17
Net Income Per Share-2.15
Book Value Per Share3.51
Tangible Book Value Per Share3.51
Shareholders Equity Per Share3.51

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -85.55%, indicates top-line expansion, while the gross profit growth, -85.58%, reveals profitability trends. EBIT growth, -170.82%, and operating income growth, -170.82%, offer insights into operational profitability progression. The net income growth, -18.84%, showcases bottom-line expansion, and the EPS growth, 72.61%, measures the growth in earnings per share.

Revenue Growth-85.55%
Gross Profit Growth-85.58%
EBIT Growth-170.82%
Operating Income Growth-170.82%
Net Income Growth-18.84%
EPS Growth72.61%
EPS Diluted Growth72.61%
Weighted Average Shares Growth333.20%
Weighted Average Shares Diluted Growth333.20%
Operating Cash Flow Growth-1871.42%
Free Cash Flow Growth-1874.62%
10-Year Operating CF Growth per Share-411.06%
5-Year Operating CF Growth per Share-411.06%
3-Year Operating CF Growth per Share-411.06%
10-Year Net Income Growth per Share-527.39%
5-Year Net Income Growth per Share-527.39%
3-Year Net Income Growth per Share-527.39%
10-Year Shareholders Equity Growth per Share1841.88%
5-Year Shareholders Equity Growth per Share1841.88%
3-Year Shareholders Equity Growth per Share1841.88%
Receivables Growth-3.09%
Inventory Growth-8848.84%
Asset Growth-34.71%
Book Value per Share Growth-86.26%
Debt Growth-49.15%
R&D Expense Growth93.26%
SGA Expenses Growth35.95%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 577,359,048.52, captures the company's total value, considering both debt and equity. Income quality, 0.80, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 1.81, gauges operational efficiency, while the research and development to revenue, 1131.47%, highlights investment in innovation. The ratio of intangibles to total assets, 0.05%, indicates the value of non-physical assets, and capex to operating cash flow, 0.02%, measures reinvestment capability.

Enterprise Value577,359,048.52
Income Quality0.80
Sales General and Administrative to Revenue1.81
Research and Development to Revenue1131.47%
Intangibles to Total Assets0.05%
Capex to Operating Cash Flow0.02%
Capex to Revenue-0.17%
Capex to Depreciation-48.98%
Stock-Based Compensation to Revenue174.39%
Graham Number13.04
Return on Tangible Assets-51.00%
Graham Net Net3.43
Working Capital296,894,000
Tangible Asset Value288,223,000
Net Current Asset Value288,087,000
Average Receivables1,911,000
Average Payables14,018,000
Average Inventory-929,750
Days Sales Outstanding49
Days Payables Outstanding139138
Days of Inventory On Hand-15465

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.33, and the price to book ratio, 4.33, reflect the market's valuation relative to the company's book value. The price to sales ratio, 19.73, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -69.38, and price to operating cash flows, -64.23, gauge market valuation against cash flow metrics.

Price Book Value Ratio4.33
Price to Book Ratio4.33
Price to Sales Ratio19.73
Price Cash Flow Ratio-64.23
Enterprise Value Multiple108.76
Price Fair Value4.33
Price to Operating Cash Flow Ratio-64.23
Price to Free Cash Flows Ratio-69.38
Price to Tangible Book Ratio3.18
Enterprise Value to Sales40.98
Enterprise Value Over EBITDA-3.36
EV to Operating Cash Flow-4.09
Earnings Yield-19.28%
Free Cash Flow Yield-15.39%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of NewAmsterdam Pharma Company N.V. (NAMS) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 87.568 in 2024.

What is the ticker symbol of NewAmsterdam Pharma Company N.V. stock?

The ticker symbol of NewAmsterdam Pharma Company N.V. stock is NAMS.

What is company IPO date?

IPO date of NewAmsterdam Pharma Company N.V. is 2021-02-09.

What is company current share price?

Current share price is 21.860 USD.

What is stock market cap today?

The market cap of stock today is 1951370062.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 29.